Publications for Jan Geliebter jan_geliebter@nymc.edu
Choi, D., Ramu, S., Park, E., Jung, E., Yang, S., Jung, W., . . . Geliebter, J., (2016). Aberrant activation of notch signaling inhibits PROX1 activity to enhance the malignant behavior of thyroid cancer cells. Cancer Research, 76(3), 582-593. doi:10.1158/0008-5472.CAN-15-1199
Hanly, E. K., Tuli, N. Y., Suriano, R., Geliebter, J., Moscatello, A. L., Darzynkiewicz, Z.,. . . Tiwari, R. K. (2016). Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells. Oncotarget, 7(8), 8676-8687. doi:10.18632/oncotarget.6779
George, A. L., Suriano, R., Rajoria, S. , Geliebter, J., Arnold, A. N., Wallack, M., . . . Tiwari, R. K. (2015). PLX4032 mediated melanoma associated antigen potentiation in patient derived primary melanoma cells. Journal of Cancer, 6(12), 1320-1330. doi:10.7150/jca.11126
Hanly, E. K., Bednarczyk, R. B., Moscatello, A. L., Halicka, H. D., Geliebter, J., Darzynkiewicz, Z., . . . Tiwari, R. K. (2015). mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget, 6(37), 39702-39713. doi:10.18632/oncotarget.4052
Hanly, E. K., Tuli, N. Y., Suriano, R., Geliebter, J., Moscatello, A. L., Darzynkiewicz, Z.,. . . Tiwari, R. K. (2015). Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells. Oncotarget, 7(8), 8676-8687. doi:10.18632/oncotarget.6779
Reyes, N., Bettin, A., Reyes, I., & Geliebter, J. (2015). Microarray analysis of the in vitro granulomatous response to Mycobacterium tuberculosis H37Ra. Colombia Medica, 46(1), 26-32. PMCID: PMC4437284
Hanly, E. K., Darzynkiewicz, Z., Zhao, H., Suriano, R., Shin, E. J., Geliebter, J., . . . Tiwari, R. K. (2014). Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. BMC Research Notes, 7, 187. doi:10.1186/1756-0500-7-187
MacEwan, M. E., Zhao, H., Iacob, C., Moscatello, A., Shin, E., Tiwari, R., Darzynkiewicz, Z.,. . . Geliebter, J. (2014). Androgen decreases proliferation of thyroid cancer cells. Cancer Research, 74(19 Suppl.), 2122. doi:10.1158/1538-7445.AM2014-2122
Rajoria, S., Hanly, E., Nicolini, A., Geliebter, J., Shin, E. J., Suriano, R. . . . Tiwari, R. K. (2014). Interlinking of hypoxia and estrogen in thyroid cancer progression. Current Medicinal Chemistry, 21(11), 1351-1360. doi:10.2174/0929867321666131201142434
Reyes, N., Correa, O., Bettin, A., Tiwari, R. K., & Geliebter, J. (2014). Expression profiles of proinflammatory chemokines in prostate cancer cell supernatants. Cancer Research, 74(19 Suppl.), 4882. doi:10.1158/1538-7445.AM2014-4882
Suriano, R., Tuli, N., Geliebter, J., Tiwari, R. K., & Wallack,M. K. (2014). Targeted inhibition of BRAF signaling in melanoma enhances the activity of a multivalent immunotherapeutic vaccine. Cancer Research, 74(19 Suppl.), 641.
Tiwari, R. K., Suriano, R., Banerjee, D., Konopa, J., Geliebter, J., & Mittelman, A. (2014). Capridine-(beta), a new class of chemotherapeutic agents for prostate cancer. Journal of Clinical Oncology, 32(15 Suppl.), e16062.
Tuli, N. Y., Cabin, J., Suriano, R., Geliebter, J., Shin, E., & Tiwari, R. K. (2014). Tumor microenvironment based modulation of thyroid cancer phenotype. Cancer Research, 74(19 Suppl.), 1107.
Wallack, M., Suriano, R., Tuli, N., George, A. L., Geliebter, J., & Tiwari, R. K. (2014). Clinical utility of combining PLX4032, a BRAF inhibitor, with a multivalent melanoma immunotherapeutic vaccine. Annals of Surgical Oncology, 21(1 Suppl.), S124.
Suriano, R., Rajoria, S., George, A. L., Geliebter, J., Tiwari, R. K., & Wallack, M. K. (2013). Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma. Molecular Clinical Oncology, 1(3), 466-472. doi:10.3892/mco.2013.97
Suriano, R., Rajoria, S., George, A. L., Geliebter, J., Wallack, M. K., & Tiwari, R. K. (2013). Ex vivo derived primary melanoma cells: Implications for immunotherapeutic vaccines. Journal of Cancer, 4(5), 371-382. doi:10.7150/jca.6625
